In the current study, we employed the E0771 syngeneic tumor model that has been previously shown responsive to both PS-targeting Abs (Bavituximab)38as well as anti-Mertk (a PS receptor of belonging to the TAM family)45. Here, STIM1 is linked to neoplasm.